Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rodney J Hicks

Showing results (451-460 of 471) with videos related to

Pageof 48
Sort By:
Nature Communications|March 2, 2022
Adaptive translational reprogramming of metabolism limits the response to targeted therapy in BRAF<sup>V600</sup> melanomaLorey K Smith, Tiffany Parmenter, Margarete Kleinschmidt, et al.
Blood|April 19, 2015
Noninvasive monitoring of diffuse large B-cell lymphoma by immunoglobulin high-throughput sequencingDavid M Kurtz, Michael R Green, Scott V Bratman, et al.
European Journal of Cancer (Oxford, England : 1990)|November 16, 2018
Rheumatic immune-related adverse events secondary to anti-programmed death-1 antibodies and preliminary analysis on the impact of corticosteroids on anti-tumour response: A case seriesEmma L Mitchell, Peter Kar Han Lau, Chloe Khoo, et al.
European Journal of Cancer (Oxford, England : 1990)|February 15, 2021
Consensus on molecular imaging and theranostics in neuroendocrine neoplasmsValentina Ambrosini, Jolanta Kunikowska, Eric Baudin, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|September 18, 2025
Fully Automated Image-Based Multiplexing of Serial PET/CT Imaging for Facilitating Comprehensive Disease PhenotypingLalith Kumar Shiyam Sundar, Sebastian Gutschmayer, Manuel Pires, et al.
BMJ Open|August 4, 2023
[<sup>18</sup>F]-fluoroethyl-L-tyrosine (FET) in glioblastoma (FIG) TROG 18.06 study: protocol for a prospective, multicentre PET/CT trialEng-Siew Koh, Hui K Gan, Clare Senko, et al.
The Lancet. Oncology|April 2, 2026
[<sup>177</sup>Lu]Lu-PSMA-617 in combination with pembrolizumab for treatment of metastatic castration resistant prostate cancer (PRINCE): a single-arm, phase 1b/2 studyShahneen Sandhu, Anthony M Joshua, Louise Emmett, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 9, 2021
High-Specific-Activity-<sup>131</sup>I-MIBG versus <sup>177</sup>Lu-DOTATATE Targeted Radionuclide Therapy for Metastatic Pheochromocytoma and ParagangliomaAbhishek Jha, David Taïeb, Jorge A Carrasquillo, et al.
European Journal of Nuclear Medicine and Molecular Imaging|May 29, 2023
Joint EANM/SNMMI procedure guideline for the use of <sup>177</sup>Lu-labeled PSMA-targeted radioligand-therapy (<sup>177</sup>Lu-PSMA-RLT)Clemens Kratochwil, Wolfgang P Fendler, Matthias Eiber, et al.
JCO Precision Oncology|February 17, 2022
Circulating Tumor DNA Analysis and Functional Imaging Provide Complementary Approaches for Comprehensive Disease Monitoring in Metastatic MelanomaStephen Q Wong, Jeanette M Raleigh, Jason Callahan, et al.
Pageof 48

Showing results (451-460 of 471) with videos related to

Sort By:
Pageof 48
Nature Communications|March 2, 2022
Adaptive translational reprogramming of metabolism limits the response to targeted therapy in BRAF<sup>V600</sup> melanomaLorey K Smith, Tiffany Parmenter, Margarete Kleinschmidt, et al.
Blood|April 19, 2015
Noninvasive monitoring of diffuse large B-cell lymphoma by immunoglobulin high-throughput sequencingDavid M Kurtz, Michael R Green, Scott V Bratman, et al.
European Journal of Cancer (Oxford, England : 1990)|November 16, 2018
Rheumatic immune-related adverse events secondary to anti-programmed death-1 antibodies and preliminary analysis on the impact of corticosteroids on anti-tumour response: A case seriesEmma L Mitchell, Peter Kar Han Lau, Chloe Khoo, et al.
European Journal of Cancer (Oxford, England : 1990)|February 15, 2021
Consensus on molecular imaging and theranostics in neuroendocrine neoplasmsValentina Ambrosini, Jolanta Kunikowska, Eric Baudin, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|September 18, 2025
Fully Automated Image-Based Multiplexing of Serial PET/CT Imaging for Facilitating Comprehensive Disease PhenotypingLalith Kumar Shiyam Sundar, Sebastian Gutschmayer, Manuel Pires, et al.
BMJ Open|August 4, 2023
[<sup>18</sup>F]-fluoroethyl-L-tyrosine (FET) in glioblastoma (FIG) TROG 18.06 study: protocol for a prospective, multicentre PET/CT trialEng-Siew Koh, Hui K Gan, Clare Senko, et al.
The Lancet. Oncology|April 2, 2026
[<sup>177</sup>Lu]Lu-PSMA-617 in combination with pembrolizumab for treatment of metastatic castration resistant prostate cancer (PRINCE): a single-arm, phase 1b/2 studyShahneen Sandhu, Anthony M Joshua, Louise Emmett, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 9, 2021
High-Specific-Activity-<sup>131</sup>I-MIBG versus <sup>177</sup>Lu-DOTATATE Targeted Radionuclide Therapy for Metastatic Pheochromocytoma and ParagangliomaAbhishek Jha, David Taïeb, Jorge A Carrasquillo, et al.
European Journal of Nuclear Medicine and Molecular Imaging|May 29, 2023
Joint EANM/SNMMI procedure guideline for the use of <sup>177</sup>Lu-labeled PSMA-targeted radioligand-therapy (<sup>177</sup>Lu-PSMA-RLT)Clemens Kratochwil, Wolfgang P Fendler, Matthias Eiber, et al.
JCO Precision Oncology|February 17, 2022
Circulating Tumor DNA Analysis and Functional Imaging Provide Complementary Approaches for Comprehensive Disease Monitoring in Metastatic MelanomaStephen Q Wong, Jeanette M Raleigh, Jason Callahan, et al.
Pageof 48